NCT05825183

Brief Summary

Early pregnancy loss is very common, approximately one in four women will experience a miscarriage in their lifetime. The etiology of pregnancy loss remains largely unknown, although genetic, anatomical, endocrinological and immunological abnormalities have been implicated. It is known that embryonic/fetal chromosomal aberrations contributed to approximately 50% of early pregnancy loss, among which 60-70% were aneuploidies, largely can be detected by the current gold standard karyotyping approach recommended by various international societies. However, the drawbacks of conventional karyotyping include the risk of culture failure, maternal cell contamination (MCC), limited detection resolution (5-10 Mb), and differential growth of specific cell lineages which could hinder the diagnosis of genetic abnormalities, particularly mosaicisms. Additional genetic factors beyond the resolution of karyotyping are not well studied.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
30mo left

Started May 2023

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress54%
May 2023Oct 2028

First Submitted

Initial submission to the registry

April 11, 2023

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 24, 2023

Completed
1 month until next milestone

Study Start

First participant enrolled

May 30, 2023

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2028

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2028

Last Updated

March 20, 2025

Status Verified

March 1, 2025

Enrollment Period

5 years

First QC Date

April 11, 2023

Last Update Submit

March 18, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Histopathologic diagnosis of chorionic villi

    Detecting site-to-site heterogeneity and detecting cryptic structural rearrangements, absence of heterozygoisity (AOH), and single-nucleotide variant (SNV).

    31 May 2028

  • Immunohistochemistry staining

    immunoassay of maternal decidua

    31 May 2028

Interventions

For managing with miscarriage or termination of pregnancy (TOP) in first trimester loss, ultrasound-guided manual vacuum aspiration (USG-MVA) is one of the treatment options. The USG-MVA device works by aspirating the uterine content via the cannula into the syringe. Furthermore, product of conception derived from USG-MVA can be sent for karyotyping analysis. POCs obtained from MVA procedure were rinsed in normal saline thoroughly in the kidney basin to minimize maternal blood. Chorionic villi were considered as a proxy of fetal genetics, appeared to be yellowish in color and tree-projection-like in appearance, floating on the surface of the waterline. Decidua are originated from the mother, appeared substantive in structure and sank in the basin. The two different types of tissues are separated from each other for different testing.

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsWomen
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Women undergoing ultrasound-guided manual vacuum aspiration (USG-MVA) will be recruited at Obstetrics and Gynaecology in The Prince of Wales Hospital

You may qualify if:

  • Women 18 years old or above
  • Women with miscarriage or TOP who are suitable candidates for MVA
  • first trimester miscarriage or TOP
  • No fetal heart beat or TOP in those with CRL 25mm
  • incomplete miscarriage or TOP with POG \<5cm
  • hemodynamically stable,
  • tolerates well with speculum examination

You may not qualify if:

  • Women who are not feasible for the MVA procedure
  • cervical stenosis
  • fibroid uterus \>12 weeks in size
  • known uterine malformation
  • bleeding disorder
  • clinically sepsis
  • inability to tolerate pelvic examination
  • History of psychological/ psychiatric problem
  • Patient refusal

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Prince of Wales Hospital

Hong Kong, Hong Kong

RECRUITING

Related Publications (6)

  • WARBURTON D, FRASER FC. SPONTANEOUS ABORTION RISKS IN MAN: DATA FROM REPRODUCTIVE HISTORIES COLLECTED IN A MEDICAL GENETICS UNIT. Am J Hum Genet. 1964 Mar;16(1):1-25. No abstract available.

    PMID: 14131871BACKGROUND
  • Klentzeris LD, Bulmer JN, Warren MA, Morrison L, Li TC, Cooke ID. Lymphoid tissue in the endometrium of women with unexplained infertility: morphometric and immunohistochemical aspects. Hum Reprod. 1994 Apr;9(4):646-52. doi: 10.1093/oxfordjournals.humrep.a138564.

    PMID: 7519197BACKGROUND
  • Bulmer JN, Morrison L, Longfellow M, Ritson A, Pace D. Granulated lymphocytes in human endometrium: histochemical and immunohistochemical studies. Hum Reprod. 1991 Jul;6(6):791-8. doi: 10.1093/oxfordjournals.humrep.a137430.

    PMID: 1757516BACKGROUND
  • Bulmer JN, Sunderland CA. Immunohistological characterization of lymphoid cell populations in the early human placental bed. Immunology. 1984 Jun;52(2):349-57.

    PMID: 6376338BACKGROUND
  • Starkey PM, Sargent IL, Redman CW. Cell populations in human early pregnancy decidua: characterization and isolation of large granular lymphocytes by flow cytometry. Immunology. 1988 Sep;65(1):129-34.

    PMID: 3181993BACKGROUND
  • Hill JA, Melling GC, Johnson PM. Immunohistochemical studies of human uteroplacental tissues from first-trimester spontaneous abortion. Am J Obstet Gynecol. 1995 Jul;173(1):90-6. doi: 10.1016/0002-9378(95)90175-2.

    PMID: 7631733BACKGROUND

MeSH Terms

Conditions

Anticipation, Genetic

Condition Hierarchy (Ancestors)

Genetic Predisposition to DiseaseDisease SusceptibilityDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Pui Wah Jacqueline Chung

    Prince of Wales Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Pui Wah Jacqueline Chung

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

April 11, 2023

First Posted

April 24, 2023

Study Start

May 30, 2023

Primary Completion (Estimated)

May 31, 2028

Study Completion (Estimated)

October 31, 2028

Last Updated

March 20, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations